v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Collaboration and other research and development revenues $ 11,890 $ 3,578 $ 14,721 $ 8,236
Operating expenses:        
Research and development 20,180 16,181 37,780 42,774
General and administrative 11,603 12,859 21,837 26,234
Restructuring and impairment charges (1,339) 26,082 (1,339) 66,935
Total operating expenses 30,444 55,122 58,278 135,943
Operating loss (18,554) (51,544) (43,557) (127,707)
Other income (expense), net:        
Interest expense related to sale of future revenues (1,061) (2,020) (2,133) (4,236)
Interest income, net 1,368 2,087 2,574 4,803
Other income (expense), net 17 (1,758) (96) (2,183)
Total other income (expense), net 324 (1,691) 345 (1,616)
Net loss $ (18,230) $ (53,235) $ (43,212) $ (129,323)
Net loss per share, basic (in dollars per share) $ (0.15) $ (0.63) $ (0.40) $ (1.54)
Net loss per share, diluted (in dollars per share) $ (0.15) $ (0.63) $ (0.40) $ (1.54)
Weighted-average common shares outstanding, basic (in shares) 119,294,615 84,412,200 108,646,137 83,737,382
Weighted-average common shares outstanding, diluted (in shares) 119,294,615 84,412,200 108,646,137 83,737,382